95 filings
ARS
2023 FY
OLMA
Olema Pharmaceuticals Inc
26 Apr 24
Annual report to shareholders
5:15pm
DEFA14A
OLMA
Olema Pharmaceuticals Inc
26 Apr 24
Additional proxy soliciting materials
5:10pm
DEF 14A
OLMA
Olema Pharmaceuticals Inc
Definitive proxy
26 Apr 24
5:07pm
S-8
OLMA
Olema Pharmaceuticals Inc
11 Mar 24
Registration of securities for employees
4:31pm
10-K
2023 FY
OLMA
Olema Pharmaceuticals Inc
Annual report
11 Mar 24
4:15pm
8-K
i7m9am24
11 Mar 24
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
4:05pm
424B3
0fxqjoq uouucxgoy
12 Feb 24
Prospectus supplement
5:16pm
EFFECT
qaf45ekp7vlauu6dsj
12 Feb 24
Notice of effectiveness
12:15am
CORRESP
uwx0zd7vc
7 Feb 24
Correspondence with SEC
12:00am
UPLOAD
4zyb0 ym8
7 Feb 24
Letter from SEC
12:00am
8-K
uxl8zvfm1f
8 Jan 24
Olema Oncology JP Morgan Conference January 2024
9:07am
8-K
dph20
8 Jan 24
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
8:18am
8-K
tez dmhec0uy
5 Jan 24
Entry into a Material Definitive Agreement
5:26pm
424B5
4jdaxvwlfju78c83ss7
5 Jan 24
Prospectus supplement for primary offering
5:25pm
8-K
1tkbegk
6 Dec 23
Regulation FD Disclosure
7:48am
8-K
htvroao8 38
5 Dec 23
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
5:15pm
8-K
hd2owl
7 Nov 23
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:10pm
8-K
eya61nx
23 Oct 23
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
7:45am